Cartesian Therapeutics Secures $150M Financing; Cash Runway into 2028

Cartesian Therapeutics has secured up to $150 million in non-dilutive financing from K2 HealthVentures, with an initial $50 million tranche already funded. This financing is expected to extend the company's cash runway into 2028 and support the advancement of multiple clinical programs. The company also provided updated timelines for its Descartes-08 trials, including topline data from the Phase 3 AURORA trial in myasthenia gravis expected in 1Q27, and data from Phase 2 TRITON (myositis) and Phase 1/2 HELIOS (JDM) trials expected in 1H27. Additionally, Chief Medical Officer Miloš Miljković will be stepping down for personal reasons.